Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

NCT01300156 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: Oxaliplatin-based chemotherapy (ESHAOx)

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]
[object Object]